Inicio
Información del autor
Autor Lina Maria Serna Higuita
Comentario :
Médica Pediatra Nefróloga, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (52)
Refinar búsqueda
Histoplasmosis diseminada y síndrome hemofagocítico en dos pacientes trasplantados renales / John Fredy Nieto Ríos ; Arbey Aristizabal Álzate ; Catalina Ocampo Kohn ; Lina Maria Serna Higuita ; Gustavo Adolfo Zuluaga Valencia
Título : Histoplasmosis diseminada y síndrome hemofagocítico en dos pacientes trasplantados renales Tipo de documento : documento electrónico Autores : John Fredy Nieto Ríos, ; Arbey Aristizabal Álzate, ; Catalina Ocampo Kohn, ; Lina Maria Serna Higuita, ; Gustavo Adolfo Zuluaga Valencia, Fecha de publicación : 2012 Títulos uniformes : Nefrología Idioma : Español (spa) Mención de responsabilidad : Jhon F Nieto-Ríos, Arbey Aristizabal-Alzate, Catalina Ocampo, Ana K Serrano-Gayubo, Lina M Serna-Higuita, Gustavo Zuluaga-Valencia Referencia : Nefrologia. 2012;32(5):683-4. DOI (Digital Object Identifier) : 10.3265/Nefrologia.pre2012.Jun.11508 PMID : 23013962 En línea : http://www.revistanefrologia.com/es/linksolver/ft/ivp/0211-6995/32/683 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4496 Histoplasmosis diseminada y síndrome hemofagocítico en dos pacientes trasplantados renales [documento electrónico] / John Fredy Nieto Ríos, ; Arbey Aristizabal Álzate, ; Catalina Ocampo Kohn, ; Lina Maria Serna Higuita, ; Gustavo Adolfo Zuluaga Valencia, . - 2012.
Obra : Nefrología
Idioma : Español (spa)
Mención de responsabilidad : Jhon F Nieto-Ríos, Arbey Aristizabal-Alzate, Catalina Ocampo, Ana K Serrano-Gayubo, Lina M Serna-Higuita, Gustavo Zuluaga-Valencia Referencia : Nefrologia. 2012;32(5):683-4. DOI (Digital Object Identifier) : 10.3265/Nefrologia.pre2012.Jun.11508 PMID : 23013962 En línea : http://www.revistanefrologia.com/es/linksolver/ft/ivp/0211-6995/32/683 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4496 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000995 AC-2012-084 Archivo digital Producción Científica Artículos científicos Disponible Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab / Catalina Vélez Echeverri ; Gustavo Adolfo Zuluaga Valencia ; Catalina Ocampo Kohn ; Arbey Aristizabal Álzate ; Lina Maria Serna Higuita ; John Jairo Zuleta Tobón ; Juan José Vanegas Ruiz
Título : Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab Tipo de documento : documento electrónico Autores : Catalina Vélez Echeverri, ; Gustavo Adolfo Zuluaga Valencia, ; Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; Lina Maria Serna Higuita, ; John Jairo Zuleta Tobón, ; Juan José Vanegas Ruiz, Fecha de publicación : 2011 Títulos uniformes : Transplantation Proceedings Idioma : Francés (fre) Idioma original : Inglés (eng) Resumen : Background: Renal transplantation is the most effective treatment for children with end-stage renal disease. Recent work suggests that induction with alemtuzumab in the pediatric population permits the use of lower doses of maintenance immunosuppressive therapy. In addition, it has a low cost compared with other induction therapies. Objective: To conduct a clinical description of pediatric renal transplant patients comparing induction protocols to evaluate graft and patient survival, infections complications, and lymphoproliferative diseases. Materials and Methods. This descriptive and retrospective study, of evaluated pediatric renal transplant patients between 2006 and 2010. Results: The agents for induction therapy were: alemtuzumab (61.5%), daclizumab (19.25%), and thymoglobulin (19.25%). Graft survival was better among the alemtuzumab group (87.5%) compared with the other two induction therapies (80%). The frequency of acute rejection episodes during the first year posttransplantation as well as chronic rejection was lower among the alemtuzumab group. Cytomegalovirus infection was noted in 30% of patients with greater frequency among those induced with alemtuzumab. Conclusion: Induction therapy with alemtuzumab was safe in a pediatric population not predisposing to a greater risk of acute or chronic rejection. Except for a greater incidence of Cytomegalovirus, there was no difference in other complications. Mención de responsabilidad : C Velez, G Zuluaga, C Ocampo, A Aristizabal, L M Serna, A K Serrano Gayubo, J A Florez, J J Zuleta, J J Vanegas Ruiz Referencia : Transplant Proc. 2011 Nov;43(9):3350-4. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2011.09.101 PMID : 22099794 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(11)01380-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3583 Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab [documento electrónico] / Catalina Vélez Echeverri, ; Gustavo Adolfo Zuluaga Valencia, ; Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; Lina Maria Serna Higuita, ; John Jairo Zuleta Tobón, ; Juan José Vanegas Ruiz, . - 2011.
Obra : Transplantation Proceedings
Idioma : Francés (fre) Idioma original : Inglés (eng)
Resumen : Background: Renal transplantation is the most effective treatment for children with end-stage renal disease. Recent work suggests that induction with alemtuzumab in the pediatric population permits the use of lower doses of maintenance immunosuppressive therapy. In addition, it has a low cost compared with other induction therapies. Objective: To conduct a clinical description of pediatric renal transplant patients comparing induction protocols to evaluate graft and patient survival, infections complications, and lymphoproliferative diseases. Materials and Methods. This descriptive and retrospective study, of evaluated pediatric renal transplant patients between 2006 and 2010. Results: The agents for induction therapy were: alemtuzumab (61.5%), daclizumab (19.25%), and thymoglobulin (19.25%). Graft survival was better among the alemtuzumab group (87.5%) compared with the other two induction therapies (80%). The frequency of acute rejection episodes during the first year posttransplantation as well as chronic rejection was lower among the alemtuzumab group. Cytomegalovirus infection was noted in 30% of patients with greater frequency among those induced with alemtuzumab. Conclusion: Induction therapy with alemtuzumab was safe in a pediatric population not predisposing to a greater risk of acute or chronic rejection. Except for a greater incidence of Cytomegalovirus, there was no difference in other complications. Mención de responsabilidad : C Velez, G Zuluaga, C Ocampo, A Aristizabal, L M Serna, A K Serrano Gayubo, J A Florez, J J Zuleta, J J Vanegas Ruiz Referencia : Transplant Proc. 2011 Nov;43(9):3350-4. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2011.09.101 PMID : 22099794 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(11)01380-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3583 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000153 AC-2011-038 Archivo digital Producción Científica Artículos científicos Disponible